SSc-PH screening includes transthoracic echocardiography, DLco and biomarkers (BNP/NT-proBNP), as early identification of SSc-PH is essential given the availability of new and effective drugs [140,141]. This evidence concerns the gene NPPB and systemic sclerosis.